ALLMedicine™ Hyperoxaluria Center
Research & Reviews 983 results
https://doi.org/10.1016/j.kint.2021.03.031
Kidney International; Martin-Higueras C, Garrelfs SF et. al.
Apr 18th, 2021 - Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH's with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 p...
https://doi.org/10.1007/s00240-021-01263-5 10.1016/S0022-5347(05)64264-4 10.1016/S0022-5347(17)64842-0 10.1007/BF00300021 10.1016/S0022-5347(17)39144-9 10.1016/j.jep.2005.11.004 10.3923/pjbs.1998.326.328 10.1136/jcp.13.2.156 10.1080/13880200600812634 10.1159/000046294 10.1152/ajprenal.00115.2003 10.1056/NEJM197503062921002 10.1073/pnas.91.24.11323 10.1097/01.ju.0000131004.03795.c5 10.1073/pnas.0307900100 10.1097/01.ju.0000150519.49495.88 10.1007/s12038-011-9056-7 10.33084/bjop.v3i4.1569 10.1016/j.jep.2004.03.016
Urolithiasis Afzal M, Alharbi KS et. al.
Apr 9th, 2021 - Evaluation of the effects of methanolic extract of Cucumis melo in ethylene glycol-induced nephrolithiasis on Wistar rats. 0.75% solution of ethylene glycol (EG) in payable water was given to produce nephrolithiasis on Wistar rats. The action of o...
https://doi.org/10.1007/s00467-021-05043-6 10.1038/nrneph.2012.113 10.1038/ki.2014.280 10.1038/ki.2014.222 10.1111/j.1600-6143.2010.03271.x 10.1056/NEJMra1301564 10.1093/ndt/gfs078 10.1111/j.1399-3046.2009.01230.x 10.1007/s004670100001 10.1007/s00467-003-1234-x 10.1016/s1569-9056(19)30291-x 10.1002/jrsm.41 10.1097/00007890-200209150-00020 10.1002/lt.24009 10.1016/j.kint.2019.08.018 10.1038/ki.2009.435 10.2215/cjn.07430711 10.1159/000086359 10.1046/j.1523-1755.1999.00619.x 10.1186/s12876-020-01349-1 10.1155/2015/634175 10.1097/TP.0b013e3181a27939 10.1111/petr.12595 10.1007/s00467-016-3324-6 10.1093/ndt/16.2.348 10.1046/j.1523-1755.1998.00876.x 10.1038/ki.1992.434 10.1111/petr.12705 10.1111/petr.13313 10.1111/ajt.12706 10.1038/sj.ki.5001758 10.12659/aot.882227 10.1097/01.Tp.0000084203.76110.Ac 10.1053/jlts.2001.28741 10.1002/lt.24167 10.1034/j.1399-3046.2000.00107.x 10.1111/petr.13406 10.1097/TP.0b013e3181a4e710 10.1093/ndt/gfq353 10.1007/s00467-017-3782-5 10.1111/petr.12376 10.1097/00007890-200108150-00012 10.1097/00007890-198806000-00031 10.1002/lt.24676 10.1034/j.1600-6143.2003.00050.x 10.1097/01.tp.0000225831.35143.06 10.1016/0002-9343(91)90539-A 10.1093/ndt/10.supp8.3 10.1016/s0022-3476(99)70095-8 10.1159/000086358 10.1093/ndt/6.7.502 10.1097/01.sla.0000133083.54934.ae 10.1093/ndtplus/sfq063 10.2215/CJN.06820613 10.1111/j.1523-1755.2004.00796.x 10.1111/petr.13457 10.1007/s00240-005-0495-1 10.1177/1536867X1801700402 10.1016/j.ekir.2020.09.022
Pediatric Nephrology (Berlin, Germany); Metry EL, van Dijk LMM et. al.
Apr 8th, 2021 - Primary hyperoxaluria type 1 (PH1) is characterized by hepatic overproduction of oxalate and often results in kidney failure. Liver-kidney transplantation is recommended, either combined (CLKT) or sequentially performed (SLKT). The merits of SLKT ...
https://doi.org/10.1016/j.urology.2021.03.014
Urology Shee K, Ahn J et. al.
Mar 28th, 2021 - Primary hyperoxaluria 1 (PH1) is a devastating condition involving recurrent urolithiasis, early end-stage renal disease and multisystemic deposition of calcium oxalate crystals. Treatment options for PH1 are limited, inevitably requiring transpla...
https://doi.org/10.1111/petr.14003
Pediatric Transplantation; Tandoi F, Cussa D et. al.
Mar 20th, 2021 - Combined liver-kidney transplantation is a therapeutic option for children affected by type 1 primary hyperoxaluria. Persistently high plasma oxalate levels may lead to kidney graft failure. It is debated whether pre-emptive liver transplantation,...
Guidelines 2 results
https://doi.org/10.1093/ndt/gfs078
Nephrology, Dialysis, Transplantation : Official Publicat... Cochat P, Hulton SA et. al.
May 1st, 2012 - Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary...
https://www.oxlumohcp.com
Use the dosing and admin guide to learn which dosing regimen is right for your patients. Review dosing and administration for OXLUMO
Drugs 1 results see all →
Clinicaltrials.gov 1,013 results
https://doi.org/10.1016/j.kint.2021.03.031
Kidney International; Martin-Higueras C, Garrelfs SF et. al.
Apr 18th, 2021 - Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH's with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 p...
https://doi.org/10.1007/s00240-021-01263-5 10.1016/S0022-5347(05)64264-4 10.1016/S0022-5347(17)64842-0 10.1007/BF00300021 10.1016/S0022-5347(17)39144-9 10.1016/j.jep.2005.11.004 10.3923/pjbs.1998.326.328 10.1136/jcp.13.2.156 10.1080/13880200600812634 10.1159/000046294 10.1152/ajprenal.00115.2003 10.1056/NEJM197503062921002 10.1073/pnas.91.24.11323 10.1097/01.ju.0000131004.03795.c5 10.1073/pnas.0307900100 10.1097/01.ju.0000150519.49495.88 10.1007/s12038-011-9056-7 10.33084/bjop.v3i4.1569 10.1016/j.jep.2004.03.016
Urolithiasis Afzal M, Alharbi KS et. al.
Apr 9th, 2021 - Evaluation of the effects of methanolic extract of Cucumis melo in ethylene glycol-induced nephrolithiasis on Wistar rats. 0.75% solution of ethylene glycol (EG) in payable water was given to produce nephrolithiasis on Wistar rats. The action of o...
https://doi.org/10.1007/s00467-021-05043-6 10.1038/nrneph.2012.113 10.1038/ki.2014.280 10.1038/ki.2014.222 10.1111/j.1600-6143.2010.03271.x 10.1056/NEJMra1301564 10.1093/ndt/gfs078 10.1111/j.1399-3046.2009.01230.x 10.1007/s004670100001 10.1007/s00467-003-1234-x 10.1016/s1569-9056(19)30291-x 10.1002/jrsm.41 10.1097/00007890-200209150-00020 10.1002/lt.24009 10.1016/j.kint.2019.08.018 10.1038/ki.2009.435 10.2215/cjn.07430711 10.1159/000086359 10.1046/j.1523-1755.1999.00619.x 10.1186/s12876-020-01349-1 10.1155/2015/634175 10.1097/TP.0b013e3181a27939 10.1111/petr.12595 10.1007/s00467-016-3324-6 10.1093/ndt/16.2.348 10.1046/j.1523-1755.1998.00876.x 10.1038/ki.1992.434 10.1111/petr.12705 10.1111/petr.13313 10.1111/ajt.12706 10.1038/sj.ki.5001758 10.12659/aot.882227 10.1097/01.Tp.0000084203.76110.Ac 10.1053/jlts.2001.28741 10.1002/lt.24167 10.1034/j.1399-3046.2000.00107.x 10.1111/petr.13406 10.1097/TP.0b013e3181a4e710 10.1093/ndt/gfq353 10.1007/s00467-017-3782-5 10.1111/petr.12376 10.1097/00007890-200108150-00012 10.1097/00007890-198806000-00031 10.1002/lt.24676 10.1034/j.1600-6143.2003.00050.x 10.1097/01.tp.0000225831.35143.06 10.1016/0002-9343(91)90539-A 10.1093/ndt/10.supp8.3 10.1016/s0022-3476(99)70095-8 10.1159/000086358 10.1093/ndt/6.7.502 10.1097/01.sla.0000133083.54934.ae 10.1093/ndtplus/sfq063 10.2215/CJN.06820613 10.1111/j.1523-1755.2004.00796.x 10.1111/petr.13457 10.1007/s00240-005-0495-1 10.1177/1536867X1801700402 10.1016/j.ekir.2020.09.022
Pediatric Nephrology (Berlin, Germany); Metry EL, van Dijk LMM et. al.
Apr 8th, 2021 - Primary hyperoxaluria type 1 (PH1) is characterized by hepatic overproduction of oxalate and often results in kidney failure. Liver-kidney transplantation is recommended, either combined (CLKT) or sequentially performed (SLKT). The merits of SLKT ...
https://doi.org/10.1016/j.urology.2021.03.014
Urology Shee K, Ahn J et. al.
Mar 28th, 2021 - Primary hyperoxaluria 1 (PH1) is a devastating condition involving recurrent urolithiasis, early end-stage renal disease and multisystemic deposition of calcium oxalate crystals. Treatment options for PH1 are limited, inevitably requiring transpla...
https://doi.org/10.1111/petr.14003
Pediatric Transplantation; Tandoi F, Cussa D et. al.
Mar 20th, 2021 - Combined liver-kidney transplantation is a therapeutic option for children affected by type 1 primary hyperoxaluria. Persistently high plasma oxalate levels may lead to kidney graft failure. It is debated whether pre-emptive liver transplantation,...
News 15 results
https://reference.medscape.com/viewarticle/944415
Feb 28th, 2021 - Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disease that is caused by a functional defect of alanine:glyoxylate aminotransferase catalysis, resulting in the overproduction of oxalate. The clinical impact of PH1 can be devastat...
https://reference.medscape.com/viewarticle/944411
Feb 28th, 2021 - Primary hyperoxaluria (PH) encompasses a group of rare genetic metabolic disorders that are characterized by the accumulation of oxalate in the kidneys and other organs. PH is categorized as type 1 (PH1), type 2 (PH2) or type 3 (PH3). An estimated...
https://www.medscape.com/viewarticle/941520
Nov 23rd, 2020 - The US Food and Drug Administration (FDA) has approved lumasiran (Oxlumo, Alnylam Pharmaceuticals) subcutaneous injection to treat children and adults with primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder that causes recurrent ki...
https://www.medscape.com/viewarticle/912061
May 1st, 2019 - Does higher urinary oxalate excretion predispose patients to kidney failure? Elevated levels of oxalate, a metabolite eliminated through the kidney, can be toxic. Oxalate nephropathy is characterized by high concentrations of oxalate in kidney tub...
http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder
For Immediate Release: November 23, 2020 Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of ...
